

LITERATUR

- Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respass R, Wiktor SZ, Chorba T, Nkengasong JN: High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among Patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire, *J Acquir Immune Defic Syndr* [2001;26\(5\):501-6](#)
- Adje-Toure C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholie S, Lackritz E, Chorba T, Nkengasong JN: Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among Patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire, *AIDS*. [2003b;17 Suppl 3:23-9](#)
- Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sasan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN: Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire, *AIDS*. [2003a;17 Suppl 3:49-54](#)
- Ahmad K: Antidepressants are sold as antiretrovirals in DR Congo, *Lancet*. [2004;363\(9410\):713](#)
- Ainsworth M, Teokul W: Breaking the silence: setting realistic priorities for AIDS control in less-developed countries, *Lancet*. [2000;356\(9223\):55-60](#)
- Akileswaran C, Lurie MN, Flanigan TP, Mayer KH: Lessons learned from use of highly active antiretroviral therapy in Africa, *Clin Infect Dis*. [2005;41\(3\):376-85](#)
- Alwano MG, Roels TH, Mokomane M, Mwasalla V, Molosiwa R, Kilmarx PH: The effect of introducing antiretroviral therapy in the public setting on utilization of voluntary counseling and testing (VCT) services in Botswana – 2001-2003, Abstract 3677, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Arasteh K, Lazzarin A, Clotet B, Lalezari J, Cooper D, Henry K: 96 week virological and immunological response and safety evaluation on enfuvirtide with an optimized background, Abstract 1058, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA, Schoenbaum EE: Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring, *Clin Infect Dis*. [2001;33\(8\):1417-23](#)
- Attaran A und Sachs J: Defining and refining international donor support for combating the AIDS pandemic, *Lancet*. [2001;357\(9249\):57-61](#)

Atwine B, Cantor-Graae E, Bajunirwe F: Psychological distress among AIDS orphans in rural Uganda, *Soc Sci Med.* [2005;61\(3\):555-64](#)

Auswärtiges Amt. Uganda: Geschichte. <http://www.auswaertiges-amt.de/www/de/laenderinfos>, [Oktober 2003](#)

Ayouba A, Tene G, Cunin P, Foupouapouognigni Y, Menu E, Kfutwah A, Thonnon J, Scarlatti G, Monny-Lobe M, Eteki N, Kouanfack C, Tardy M, Leke R, Nkam M, Nlend AE, Barre-Sinoussi F, Martin PM, Nerrienet E: Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon, *J Acquir Immune Defic Syndr.* [2003;34\(3\):274-80](#)

Badri M und Wood R: Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings, *AIDS.* [2003;17:541-545](#)

Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A: Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population, *AIDS.* [2000;14\(4\):357-66](#)

Bartlett JG und Gallant JE: *Medical Management of HIV Infection.* Johns Hopkins University School of Medicine (Hrsg). Baltimore, Maryland [2001](#)

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS: Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings, *Antivir Ther.* [2003;8\(5\):379-84](#)

Binswanger HP: Scaling Up HIV/AIDS programs to national coverage, *Science.* [2000;288\(5474\):2173-6](#)

Blake M und Sherer R: Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence, *Clin Infect Dis.* [2000;30:96-116](#)

Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly RP, Conway B, Routy JP: Resistance to antiretroviral drugs in patients with primary HIV-1 infection, *Int J Antimicrob Agents.* [2000;16\(4\):429-34](#)

- Brites CR, Angelo ALD, Dias C, Torres AJ, Ramos AM, Lima M, Martins-Netto E: Evaluating the absolute lymphocyte count as a substitute for CD4 count in the follow up of AIDS patients under HAART, Abstract 3169, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Brook MG, Dale A, Tomlinson D, Waterworth C, Daniels D, Forster G: Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units, *AIDS Patient Care STDS* [2001;15\(9\):491-4](#)
- Brown S, Friedland GH, Bodasing U: Assessment of adherence to antiretroviral therapy in HIV-infected South African adults, Abstract 635, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Byakika T, Oyugi JH, Tumwikirize WA, Katabira ET, Mugenyi PN, Bangsberg DR: Ability to Purchase and Secure Stable Therapy are Significant Predictors of Non-adherence to Antiretroviral Therapy in Kampala, Uganda, Abstract 170, 10th CROI [2003](#), Boston, USA
- Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugenyi PN, Bangsberg DR: Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy, *Int J STD AIDS*. [2005;16\(1\):38-41](#)
- Cale D, Naik E, Taylor R, Onkst CL, Ellingstad K, Nadler J: Sociodemographic and behavioral factors associated with non-adherence to Highly Active Antiretroviral Therapy (HAART), Abstract 6057, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, *Lancet*. [1998;351\(9102\):543-9](#)
- Castagna A, Biswas P, Beretta A, Lazzarin A: The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development, *Drugs*. [2005;65\(7\):879-904](#)
- CDC: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, *MMWR*. [1992;41:1-19](#)
- Chaiyamahapark S: Early clinical outcome of patients enrolled by national access to antiretroviral for pha programme in region 9, Abstract 731, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Chen R, Westfall A, Cloud G, Chatham A, Acosta E, Raper J, Heudebert B, Saag M: Long-term survival after initiation of antiretroviral therapy, Abstract 341, 8th CROI [2001](#), Chicago, USA

Chen Z, Hu B, Huang W: HIV-1 mutants less susceptible to SCH-D, a novel small molecule antagonist of CCR5, Abstract 396, 9th CROI [2002](#), Seattle, USA

Chesney MA, Morin M, Sherr L: Adherence to HIV combination therapy, Soc Sci Med. [2000a:50\(11\):1599-605](#)

Chesney MA: Factors affecting adherence to antiretroviral therapy, Clin Infect Dis. [2000b:30 Suppl.2:171-6](#)

CIA: The world fact book, <http://www.cia.gov/cia/publications/factbook>, [18.12.2003](#)

Cock de KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick DJ, Rogers M, Shaffer N: Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice, JAMA. [2000:283\(9\):1175-82](#)

Commonwealth Local Government Forum: Country Profile: Uganda. The Local Government System in Uganda, <http://www.dodec.co.uk> , [September 2004](#)

Concorde Coordinating Committee: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, Lancet. [1994:343\(8902\):871-81](#)

Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M: When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study, AIDS. [2001:15\(8\):983-90](#)

Cunningham CK, Chaix ML, Rekeciewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316, J Infect Dis. [2002:186\(2\):181-8](#)

- Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N: Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors, *J Med Chem.* [2005;48\(1\):111-20](#)
- Delta Coordinating Committee: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, *Lancet.* [1996;348\(9023\):283-91](#)
- De Clercq E: Emerging anti-HIV drugs, *Expert Opin Emerg Drugs.* [2005;10\(2\):241-73](#)
- Demarest J, Bonny T, Vavro C, La Branche C, Kitrinis K, McDanal C, Sparks S, Chavers S, Castillo S, Elrick D, McCarty D, Whitcomb J, Huang W, Petropoulos C, Piscitelli S: HIV-1 co-receptor tropism in treatment naive and experienced subjects, Abstract 1136, 44th ICAAC [2004](#), Washington, USA
- Desclaux A, Ciss M, Taverne B, Sow PS, Egrot M, Faye MA, Laniece I, Sylla O, Delaporte E, Ndoye I: Access to antiretroviral drugs and AIDS management in Senegal, *AIDS.* [2003;17 Suppl 3:95-101](#)
- DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services (DHHS), <http://AIDSinfo.nih.gov>, [October 2005](#)
- Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T: Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire, *AIDS.* [2003;17 Suppl 3:5-15](#)
- Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntyry JA, Harlow SD: Gender-based violence, relationship power and risk of HIV infection among women attending antenatal clinics in South Africa, *Lancet.* [2004;363:1415-1421](#)
- Duong M, Piroth L, Grappin M, Forte F, Peytavin G, Buisson M, Chavanet P, Portier H: Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens, *HIV Clin Trials.* [2001;2\(2\):128-35](#)
- Egger M: Progression of HIV-1 infected drug-naïve patients starting potent antiretroviral therapy: multicohort analysis of 12,040 patients, Abstract LB-18, 41st ICAAC [2001](#), Chicago, USA

- Eholié SP, Bissagnéné E, Ouiminga M, Kangah-Koffi C, Diakhité N, Ehui E, Adjé-Touré C, Kakou AR, Kadio A: Adherence to HAART and its principal determinants in the HIV infected adults in Abidjan (Cote d'Ivoire), Abstract 6031, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Ekong E, Idemyor V, Akinlade O, Uwah A: Challenges to antiretroviral drug therapy in resource-limited settings: the Nigerian experience, Abstract 596, 11th CROI [2004](#), San Francisco, USA
- Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M: Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study, Arch Intern Med. [2000;160\(8\):1134-40](#)
- Ergrot M, Taverne B, Ciss M, Ndoye I. La circulation des médicaments antirétroviraux au Sénégal. In : Desclaux A, Lanière I, Ndoye I, Taverne B (Hrsg.): L'initiative, sénégalaise d'accès aux médicaments antirétroviraux. Analyses économiques, sociales, comportementales et médicales, Paris, ANRS. [2002:221-231](#)
- Farber CM, Barath AA, Dieye T: The effects of immunization in human immunodeficiency virus type 1 infection, N Engl J Med. [1996;335\(11\):817](#)
- Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY: Community-based approaches to HIV treatment in resource-poor settings, Lancet. [2001a;358\(9279\):404-9](#)
- Farmer P, Leandre F, Mukherjee J, Gupta R, Tarter L, Kim JY: Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy), Bull World Health Organ. [2001b;79\(12\):1145-51](#)
- Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, Zavolan M, van der Ryst E: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1, Nat Med. [2005 Oct 5: \[Epub ahead of print\]](#)
- Ferris DC, Dawood H, Chiasson MA, Diamond B, Hammer SM: Self-reported adherence to antiretroviral therapy and virologic outcomes in HIV-infected persons in Durban, KwaZulu Natal, South Africa . Abstract 6070, 15th International AIDS Conference [2004](#), Bangkok, Thailand

- Fowler MG, Moorman A, Tong TC, Holmberg S, Greenberg AE: Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz? *J Acquir Immune Defic Syndr*. [2003:34\(3\):348-50](#)
- Franti M, Nagashima K, Maddon P, Burton DR, Olson W, Poignar P: The CCR5 co-receptor inhibitor PRO 140 effectively controls established HIV-1 infection in vivo, Abstract 403, 9th CROI [2002b](#), Seattle, USA
- Franti M, O'Neill T, Maddon P, Burton DR, Poignar P, Olson W: PRO 542 (CD4-IgG2) has a profound impact on HIV-1 replication in the Hu-PBL-SCID mouse model. Abstract 401, 9th CROI [2002a](#), Seattle, USA
- Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, Weber JN, McClure MO: Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients, *AIDS*. [2001:15\(12\):1493-502](#)
- Gesundheitsministerium, Uganda: Ministry of Health online, health facilities. www.health.go.ug, [3.2.2004](#)
- Gialloreti LE, De Luca A, Perno CF, Liotta G, Narciso P, Abdel Magid N, Marazzi MC, Vella S, Palombi L: Increase in Survival in HIV-1 infected Subjects in Matola, Mozambique, after the Introduction of Combination Therapy With Generic-manufactured Antiretrovirals: Preliminary results from the DREAM Cohort, Abstract 175, 10th CROI [2003](#), Boston, USA
- Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR: Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale (VAS), Abstract 5911, 15th International AIDS Conference [2004b](#), Bangkok, Thailand
- Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS: Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation, *J Immunol*. [1996:157\(3\):1271-8](#)
- Gottlieb MS, Schroff R, Schanker HW, Weisman JD, Fan PT, Wolf RA, Saxon A: Pneumocystis carinii pneumonia and mucosal candidiasis in previous healthy homosexual men, *N Engl J Med*. [1981:305:1425-1431](#)
- Government of Uganda: Districts, Kabarole, www.government.go.ug, [3.2.2004](#)

- Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy, *Ann Intern Med.* [2000;133\(6\):401-10](#)
- Gross R, Bilker WB, Friedman HM, Strom BL: Effect of adherence to newly initiated antiretroviral therapy on plasma viral load, *AIDS.* [2001;15\(16\):2109-17](#)
- Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, et al.: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study, *N Engl J Med.* [1992;326\(7\):437-43](#)
- Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, *N Engl J Med.* [1996;335\(15\):1081-90](#)
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, *N Engl J Med.* [1997;337\(11\):725-33](#)
- Hanna G, Lalezari L, Hellinger J, Wohl D, Masterson T, Fiske W, Kadow J, Lin P, Giordano M, Colonna M, Grasela D: Antiviral activity, safety and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects, Abstract 141, 11th CROI, [2004](#), San Francisco, USA
- Hanson S: The problems of allocating large sums of money for AIDS, *Lancet Infect Dis.* [2003;3\(8\):464-5](#)
- Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa, *Lancet.* [2001;358\(9279\):410-4](#)
- Harrigan PR, Asselin JJ, Dong D, Wynhoven B, Brumme C, Brumme Z, Hogg RS, Montaner JS, Goodrich J, Mayer H: Prevalence, predictors and clinical impact of baseline HIV co-receptor usage in a large cohort of antiretroviral naive individuals starting HAART, Abstract 3117, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Hazuda D: Integrase Inhibitors, Abstract MoOrA137, 14th International AIDS Conference [2002](#), Barcelona, Spain

Hoffmann C, Kamps BS: Introduction, in Hoffmann C, Rockstroh JK und Kamps BS (Hrsg.): HIV.NET 2005, Steinhäuser Verlag, Wuppertal-Beyenburg [2005](#), [S. 23](#)

Hoffmann C, Mulcahy F: Monitoring, in Hoffmann C, Rockstroh JK und Kamps BS (Hrsg.): HIV.NET 2005, Steinhäuser Verlag, Wuppertal-Beyenburg [2005b](#), [S. 250-263](#)

Hoffmann C, Mulcahy F: When to start HAART, in Hoffmann C, Rockstroh JK und Kamps BS (Hrsg.): HIV.NET 2005, Steinhäuser Verlag, Wuppertal-Beyenburg [2005a](#), [S. 174-89](#)

Hoffmann C: Opportunistic Infections, in Hoffmann C, Rockstroh JK und Kamps BS (Hrsg.): HIV.NET 2005, Steinhäuser Verlag, Wuppertal-Beyenburg [2005b](#), [S. 365-444](#)

Hoffmann C: Perspective, in Hoffmann C, Rockstroh JK und Kamps BS (Hrsg.): HIV.NET 2005, Steinhäuser Verlag, Wuppertal-Beyenburg [2005a](#), [S. 85-9](#)

Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy, JAMA. [1998a:279\(6\):450-4](#)

Hogg RS, Weber AE, Craib KJ, Anis AH, O'Shaughnessy MV, Schechter MT, Montaner JS: One world, one hope: the cost of providing antiretroviral therapy to all nations, AIDS. [1998b:12\(16\):2203-9](#)

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy, JAMA. [2001:286\(20\):2568-77](#)

Hoover DR: Would confirmatory retesting of CD4+ cells to verify AIDS status be too expensive? J Acquir Immune Defic Syndr. [1993:6\(5\):537-9](#)

HORIZON Korrespondent: AIDS drugs selling in city streets, www.who.int/hiv [22.1.2004](#)

- Hornberger J, Green J: Clinical prognosis of enfuvirtide in combination with an optimized background regimen among categories of baseline CD4+ cell count and HIV antiretroviral resistance, Abstract 478, 2nd IAS [2003](#), Paris, France
- Horton R: African AIDS beyond Mbeki: tripping into anarchy, *Lancet*. [2000;356\(9241\):1541-2](#)
- Hosseini pour M, Namarika D, Magomero K, Martinson F, Phiri S, Neuhann F, Luftl S: The Malawian Antiretroviral Program: The First Year Experience with Triomune, Abstract 172, 10th CROI [2003](#), Boston, USA
- Hosseini pour M, Neuhann F, Kanyama C, Namarika D, Phiri S: Mortality is the leading cause of loss to follow-up among antiretroviral patients in Malawi, Abstract 594, 11th CROI [2004a](#), San Francisco, USA
- Hosseini pour MC, Kanyama C, Nkhalamba T, Phiri S, Weigel R, Funsani C, Potani P, Namakwa D, Lugalia L, van der Horst C, Hoffman I, Neuhann F: Safety and Efficacy of D4T/3TC/NVP among HIV positive Adults in Lilongwe, Malawi, Abstract 4626, 15th International AIDS Conference [2004b](#), Bangkok, Thailand
- Individual Members of the Faculty of Harvard University: Consensus Statement on Antiretroviral Treatment for AIDS in Poor Countries, Harvard, Boston, [2001](#)
- International AIDS Society: Place of antiretroviral drugs in the treatment of HIV-infected people in Africa, *AIDS*. [1999;13\(2\):IAS1-3](#)
- Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC: Treatment of advanced human immunodeficiency virus Type 1 disease with the viral entry inhibitor PRO 542, *Antimicrob Agents Chemother*. [2004;48:423-9](#)
- Jaffar S, Govender T, Garrib A, Welz T, Grosskurth H, Smith PG, Whittle H, Bennish ML: Antiretroviral treatment in resource-poor settings: public health research priorities, *Trop Med Int Health*. [2005;10\(4\):295-9](#)
- Jeannin A, Pinoges L, Calmy A, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Tassié JM, Brasher C, Balandine S, Fedida G, Ford N, Ferradini L: Clinical and Virological Outcomes of Patients on HAART in a Large-scale Simplified Treatment Program in a Rural District of Malawi, Abstract 625B, 12th CROI [2005](#), Boston, Massachusetts, USA

- Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK: N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion, *Antimicrob Agents Chemother.* [2004:48:4349-59](#)
- Jourdain G, Fregonese F, Kanabkaew C, Pattanapornpan N, Peongjakta R, Kanjanavanit S, Thanasri S, Cowatcharagul W, Sirijittrakorn P, Ngo-Giang-Huong N, Lallemand M: HIV medicine and HAART in community hospitals in Northern Thailand, Abstract 626, 15th International AIDS Conference [2004a](#), Bangkok, Thailand
- Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemand M: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy, *N Engl J Med.* [2004b:351\(3\):229-40](#)
- Kabugo C, Katureebe CN, Mbidde MJ, Kimuli IR, Esiru G, Kituuka P, Bassani L, Okong P: Antiretroviral therapy in MTCT-Plus program at St Francis Hospital, Nsambya, Uganda, Abstract 3087, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, Downing R, Mermin J, Weidle PJ: Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses, *J Acquir Immune Defic Syndr.* [2005:38\(5\):578-83](#)
- Kaiser Family Foundation: HIV/AIDS Policy Fact Sheet, www.kff.org, Washington DC, [15.11.2005](#)
- Kallings LO und Vella S: Access to HIV/AIDS care and treatment in the south of the world, *AIDS.* [2001:15\(7\):IAS1-3](#)
- Kamwenge District Local Government: Annual work plan for financial year 2003/2004, Kamwenge District Local Government (Hrsg.), [2003](#)
- Kasper T, Hildebrand H, Tshabane N, Louis F, Reuter H: Antiretroviral therapy in primary health care centers in a South African township, Abstract 1095, 14th International Conference on AIDS [2002](#), Barcelona, Spanien

- Katzenstein D, Laga M, Moatti JP: The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa, *AIDS*. [2003;17 Suppl 3:1-4](#)
- Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA: Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy, *AIDS*. [2000;14\(8\):959-69](#)
- Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M: Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients, *AIDS Res Hum Retroviruses*. [2002;18\(16\):1181-7](#)
- Kelly JA, Otto-Salaj LL, Sikkema KJ, Pinkerton SD, Bloom FR: Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention, *Health Psychol*. [1998;17\(4\):310-9](#)
- Kimani J, Irungu E, Njeri J, Kariri A, Wachihi C, Plummer FA: Total Lymphocytes count is a poor surrogate for CD4+T- cells count amongst HIV-1 infected clients in Nairobi, Kenya, Abstract 399, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH: Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival, *N Engl J Med*. [1996;334\(11\):701-6](#)
- Koblavi-Dème S, Maran M, Kabran N, Borget MY, Kalou M, Kestens L, Maurice C, Sassan-Morokro M, Ekpini ER, Roels TH, Chorba T, Nkengasong JN: Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy, *AIDS*. [2003;17 Suppl 3:17-22](#)
- Kolber MA, Gabr AH, De La Rosa A, Glock JA, Jayaweera D, Miller N, Dickinson GM: Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads, *AIDS*. [2002;16\(4\):537-42](#)
- Kolte L, Dreves AM, Ersboll AK, Strandberg C, Jeppesen DL, Nielsen JO, Ryder LP, Nielsen SD: Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy, *J Infect Dis*. [2002;185\(11\):1578-85](#)

- Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsly S, Cohen C, Kuritzkes DR, Eron JJ Jr., Chung J, DeMasi R, Donatucci C, Drobnes C, Delehanty J, Salgo M: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America, *N Engl J Med*. [2003;348:2175-85](#)
- Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S: Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults, *AIDS*. [2005;19\(14\):1443-8](#)
- Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, Kane CT, Delaporte E, Sow PS, Faye MA, Gueye M, Peytavin G, Dalban C, Girard PM, Ndoye I: Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal, *AIDS*. [2003;17\(7\):1017-22](#)
- Laniece I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, Sylla O, Delaporte E, Ndoye I: Adherence to HAART and its principal determinants in a cohort of Senegalese adults, *AIDS*. [2003;17 Suppl 3:103-8](#)
- Laurence J: The cost effectiveness of antiretroviral therapy for HIV disease, *N Engl J Med*. [2001;345\(1\):68](#)
- Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, Gueye M, Laniece I, Toure Kane C, Liegeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study, *AIDS*. [2002;16\(10\):1363-70](#)
- Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study, *Lancet*. [1999;353\(9156\):863-8](#)
- Le Moing V, Thiebaut R, Chene G, Leport C, Cailleton V, Michelet C, Fleury H, Herson S, Raffi F: Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen, *J Infect Dis*. [2002;185\(4\):471-80](#)
- Lerner BH, Gulick RM, Dubler NN: Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV-disease, *Ann Intern Med* [1998;129:573-8](#)
- Liechty CA und Bangsberg DR: Doubts about DOT: antiretroviral therapy for resource-poor countries, *AIDS*. [2003;17\(9\):1383-7](#)

Lin PF, Guo K, Fridell R, Ho HT, Yamanaka G, Colunno R: Identification and characterization of a novel inhibitor of HIV-1 entry – II: Mechanism of Action, Abstract 10, 9th CROI [2002a](#), Seattle, USA

Lin PF, Robinson B, Gong YF, Ricarrdi K, Guo Q, Deminie C, Rose R, Wang T, Meanwell N, Yang Z, Wang H, Zhang T, Colunno R: Identification and characterization of a novel inhibitor of HIV-1 entry – I: virology and resistance, Abstract 9, 9th CROI [2002b](#), Seattle, USA

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV, *N Engl J Med.* [2002;347\(6\):385-94](#)

Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS: A comparison study of multiple measures of adherence to HIV protease inhibitors, *Ann Intern Med.* [2001;134\(10\):968-77](#)

Lockmann S, Smeaton L, Shapiro RL, Wester C, Thior I, Stevens L, MD4, Ndung'u T, Phd4, Moffat C, Asmelash A, Ndase P, Arimi P, Owor A, Van Widenfelt E, Lagakos S, Essex M: Maternal and infant response to nevirapine - based antiretroviral treatment following peripartum single-dose NVP or placebo, Abstract, 43rd ISDA [2005](#), San Francisco, USA

Loetzer KD, überarbeitetet von Schweizer-Ehrler G: Landeskundliche Informationsseiten: Uganda, www.dse.de, [15.10.2005](#)

Maggiolo F, Migliorino M, Piralì A, Pravettoni G, Caprioli S, Suter F: Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment, *J Acquir Immune Defic Syndr.* [2000;25\(1\):36-43](#)

Mbewu A: Antiretroviral therapy is only part of it, *Bull World Health Organ.* [2001;79\(12\):1152](#)

McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP: Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic, *Clin Infect Dis.* [2001;33\(5\):700-5](#)

- Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P: Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'Ivoire, *AIDS*. [2003;17 Suppl 3:69-77](#)
- Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA: Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine, *AIDS*. [2000;14\(11\):1545-52](#)
- Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group, *Lancet*. [1998;352\(9142\):1725-30](#)
- Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretroviral therapy, *AIDS*. [1999;13\(14\):1933-42](#)
- Mpiima S, Wangalawa S, Mugisha K, Namusoke D, Dambya I, Onkongo B: Increased demand for VCT services driven introduction of HAART in Masaka district, Abstract 7940, 3rd IAS [2005](#), Rio de Janeiro, Brasilien
- Munderi P, Kityo Mutuluza C, Reid A, Walker AS: CD4 response to HAART in previously untreated adults with HIV infection in Afrika: the DART trial, Abstract 592, 11th CROI [2004](#), San Francisco, USA
- Muñoz-Moreno JA, Fumaz CR, Negredo E, Moltó J, Gel S, Puig J, Martínez E, Ferrer MJ, Clotet B: Impact of a once-daily antiretroviral regimen on quality of life and adherence to treatment of HIV infected patients with viral load suppression, Abstract 4704, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Mutuluza CK, Walker S, Kaleebu P, Robertson V, Enzama R, Burke A, Yirell D, Reid A, Munderi P, Gibb D, Gilks C, Mugenyi P, Grosskurth H, Hakim J, Pillay D: Short-term Virologic Response to a Triple Nucleoside/Nucleotide Analogue Regimen in Adults with HIV Infection in Africa within the DART Trial and the DART Trial, Abstract 22, 12th CROI [2005](#), Boston, Massachusetts, USA
- Myer L, Thompson A, Rabkin M, Abrams EJ, El-Sadr WM: The impact of antiretroviral therapy on condom and contraceptive use among women enrolled in HIV primary care in resource-limited settings, Abstract 3689, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Naprvnik S, Poole C, Thomas JC, Eron JJ Jr: Gender difference in HIV RNA levels: a meta-analysis of published studies, *J Acquir Immune Defic Syndr.* [2002;31\(1\):11-9](#)

Ndhlovu F, Kasonde DRD: Towards Identifying and utilising existing community capacity for information, education, communication and advocacy in the introduction of universal access to anti-retroviral therapy, Abstract 1468, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Ndiaye I, Sow PS, Gueye NFN, Diouf LM, Gueye PM, Bassene E, Kane NCT, Diaw A, Mboup S: Clinical trial on the feasibility and the immuno-virologic efficacy and safety of Fortovase/Ritonavir regimen in Resource-Limited Settings: Case of Senegal, Abstract 182, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Ngabonziza M, Martinez W, Murray D, Ngirabatware B, Mukadi YD, Stuart L: ART introduction in a community health center in Rwanda. Abstract 7488, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Nguyen VK, Grennan T, Peschard K, Tan D, Tiendrebeogo I: Antiretroviral use in Ouagadougou, Burkina Faso, *AIDS.* [2003;17 Suppl 3:109-11](#)

O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, Yeramian C, Mao SH, Zack JA: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination, *Blood.* [1995;86:1082-9](#)

Oldfield V, Keating GM, Plosker G: Enfuvirtide: a review of its use in the management of HIV infection, *Drugs.* [2005;65\(8\):1139-60](#)

Omes C, Schuman M, Kamesigwa J, Demeester R, Mukakalisa J, Parisel A, Kayibanda E, Arendt C: Adherence to antiretroviral (ARV) therapy among advanced-stage, indigent patients in the funded ESTHER programme in Kigali, Rwanda, Abstract 658, 15th International AIDS Conference [2004](#), Bangkok, Thailand

Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, Wagels T, Bernasconi E, Meienberg F, Rickenbach M, Weber R: Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l, *AIDS.* [2002;16\(10\):1371-81](#)

- Orrell C, Bangsberg DR, Badri M, Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa, *AIDS*. [2003;17\(9\):1369-75](#)
- Osho OB, Ogun SA, Odusoga OL, Daniel OL, Oluwole FA, Salako AA, Ogundahunsi O, Falola OL, Ogunfowora O, Oladapo OT, Kolapo K, Boyle BA: Absolute lymphocyte count as a substitute for CD4 count in a limited resource area; Sagamu, Ogun state, Nigeria, Abstract 3102, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Oyugi JH, Byakika JT, Ragland K, Mugenyi P, Kityo C, Mugerwa R, Bangsberg DR: Treatment outcomes and Adherence to Generic Triomune® and Maxivir® therapy in Kampala, Uganda, Abstract 5912, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, *N Engl J Med*. [1998;338\(13\):853-60](#)
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection, *Ann Intern Med*. [2000;133\(1\):21-30](#)
- Pawinski R: Community attitudes to HIV/AIDS, *S Afr Med J*. [2001;91\(6\):448](#)
- Pérez-Molina JA, Arribas JR, Iribarren JA, Knobel H, Ribera E, Rubio R, Vicina P: Adherence, treatment satisfaction and effectiveness of Once-Daily (QD) vs Twice-Daily (BID) antiretroviral therapy (AT), in a large prospective observational cohort (CUVA Study), Abstract 6021, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Phair JP, Mellors JW, Detels R, Margolick JB, Munoz A: Virologic and immunologic values allowing safe deferral of antiretroviral therapy, *AIDS*. [2002;16\(18\):2455-9](#)
- Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load, *JAMA*. [2001;286\(20\):2560-7](#)

- Popp D, Fisher JD: First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world, *AIDS*. [2002;16\(4\):676-8](#)
- Pozniak AL, Fatkenheuer G, Johnson M, et al.: Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients, Abstract 443, 43rd ICAAC [2003](#), Chicago, USA
- Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA: Immune dysfunction and immune restoration disease in HIV patients given HAART, *J Clin Virol*. [2001;22:279-87](#)
- Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugenyi P, Munderi P, Darbyshire J: Antiretroviral treatment in resource-poor settings: clinical research priorities, *Lancet*. [2002;360\(9344\):1503-5](#)
- Ravaux I, Montana M, Darque A, Gallais H, Gensollen S, Timon-David P, Bongrand MC: Compliance limiting-factors of ARV treatment: Patients' point of view, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW: Sensitivity of HIV- 1 to entry inhibitors correlates with envelope: Co-receptor affinity co-receptor density, and fusion kinetics, Abstract 23, 10th CROI [2003](#), Boston, USA
- Reeves JD, Piefer AJ: Emerging drug targets for antiretroviral therapy, *Drugs*. [2005;65\(13\):1747-66](#)
- Reynolds SJ, Bartlett JG, Quinn TC, Beyrer C, Bollinger RC: Antiretroviral therapy where resources are limited, *N Engl J Med*. [2003;348\(18\):1806-9](#)
- Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G: Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA, *J Clin Invest*. [2000;105\(6\):777-82](#)
- Romanelli F, Empey K, Pomeroy C: Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection, *AIDS Patient Care STDS*. [2002;16\(9\):405-11](#)
- Sachs JD: A new global commitment to disease control in Africa, *Nat Med*. [2001;7\(5\):521-3](#)

Salaniponi F: Using lessons learned in the control of tuberculosis to design a structured framework for providing antiretroviral therapy in Malawi, *Adv Studies Med* [2001:1:480-2](#)

Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, Ghys PD, Schwartländer B: Integrating HIV prevention and treatment: from slogans to impact, *PloS Medicine*, [2005:1\(2\):e16](#)

Sanne I, Ive P, McIntyre J, Gray G, Mohpapi L, Wood R: Successful antiretroviral therapy in clinical research in South Africa, Abstract 321, 1st IAS Conference on Pathogenesis and Treatment [2001](#), Buenos Aires, Argentinien

Schols D, Claes S, Hatse S, Princen K, Vermeire K, De Clercq E, Skerlj R, Bridger G, Calandra G: Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist, Abstract 563, 10th CROI [2003](#), Boston, USA

Schols D, Vermeire K, Hatse S, Princen K, Clercq ED, Calandra G, Fricker S, Nelson K, Labrecque J, Bogucki D, Zhou Y, Skerlj R, Bridger G: In vitro anti-HIV activity profile of AMD887, a novel CCR5-antagonist, in combination with the CXCR4 inhibitor AMD070, Abstract 539, 11th CROI [2004](#), San Francisco, USA

Schooley RT: Antiretroviral chemotherapy, in Wormser (Hrsg.): AIDS and other manifestations of HIV infection, Lippincott-Raven, Philadelphia, USA, [1998](#)

Schürmann D, Rouzier R, Nourgarede R, Reynes J, Fatkenheuer G, Raffi F, Michelet C, Tarral A, Hoffmann C, Kiunke J, Sprenger H, Van Lier J, Sansone A, Jackson M, Laughlin M: SCH D: Antiviral activity of a CCR5 receptor antagonist, Abstract 140, 11th CROI [2004](#), San Francisco, USA

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance, *Clin Infect Dis*. [2003:37\(8\):1112-8](#)

Singler J, Farmer P: Treating HIV in resource-poor settings, *JAMA*. [2002:288\(13\):1652-3](#)

Solberg P, Were W, Furmanski L, Coutinho A, Kaharuzza FM, Ransom R, Downing R, Mermin JH: Comparison of clinical criteria and CD4 cell counts to determine eligibility for antiretroviral therapy in Uganda, Abstract 4491, 15th International AIDS Conference [2004](#), Bangkok, Thailand

- Souville M, Msellati P, Carrieri MP, Brou H, Tape G, Dakoury G, Vidal L: Physicians' knowledge and attitudes toward HIV care in the context of the UNAIDS/Ministry of Health Drug Access Initiative in Côte d'Ivoire, *AIDS*. [2003;17 Suppl 3:79-86](#)
- Sow PS, Schillevoort I, Kityo C, Bissagnene E, Otieno CF, Waalberg E, Lange JM: Implementing antiretroviral treatment in resource-limited settings: clinical results from four African countries, Abstract 7504, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Spacek LA, Mwesigire D, Shihab H, McKellar M, Ronald A, Kanya MR, Quinn TC: Treatment outcomes at the Mulago Hospital AIDS in Kampala, Uganda: A resource-limited setting, Abstract 7584, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Steele RH, Keogh GL, Quin J, Fernando SL, Stojkova V: Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence, *Int J STD AIDS*. [2002;13\(11\):748-54](#)
- Sterling TR, Chaisson RE, Bartlett JG, Moore RD: CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART, Abstract 519, 8th CROI [2001b](#), Seattle, USA
- Sterling TR, Chaisson RE, Moore RD: HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy, *AIDS*. [2001a;15\(17\):2251-7](#)
- Stephenson J, Obasi A: HIV risk-reduction in adolescents, *Lancet*. [2004;363:1177](#)
- Stone N, Dunaway S, Flexner C, Calandra G, Wiggins I, Conley J, Synder S, Tierney C, Hendrix C: Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects, Abstract 4475, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Stone VE, Jordan J, Tolson J, Miller R, Pilon T: Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral Therapy: Self-Report of the Relative Importance of Multiple Attributes of Highly Active Antiretroviral Therapy (HAART) Regimens in Predicting Adherence, *J Acquir Immune Defic Syndr*. [2004;36\(3\):808-816](#)

- Tamamura H, Otaka A, Fujii N: Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides, *Curr HIV Res.* [2005;3\(4\):289-301](#)
- Teshale EH, Hanson DL, Sullivan PS, Wolfe MI: Can weight gain be used as a marker for viral load response in HIV-infected patients following initiation of highly active antiretroviral therapy (HAART)? Abstract 3107, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Torres R, Reebye U: Compliance to QD dosing versus BID/TID dosing of antiretroviral agents in rural North Carolina HIV/AIDS population, Abstract 678, 15th International AIDS Conference [2004](#), Bangkok, Thailand
- Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC: Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140, *J Virol.* [2001;75\(2\):579-88](#)
- Uganda Bureau of Statistics: Projected mid-year population projections by region and district, 1991-2015, [2002](#) www.ubos.org/2002census.html, [13.02.2004](#)
- Uganda Communication Commission: Kyenjojo District, www.kyenjojo.go.ug/overview/health.htm, [18.12.2003](#)
- UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance: Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom, *BMJ.* [2001;322\(7294\):1087-8](#)
- UN High Commissioner for Human Rights: The right of everyone to the enjoyment of the highest attainable standard of physical and mental health. Commission on Human Rights resolution 2002/31, Office of the United Nations High Commissioner for Human Rights, www.unhcr.ch, Genf, [2001, 15.4.2004](#)
- UNAIDS: Report on the global HIV/AIDS epidemic, UNAIDS/00.13E, www.unaids.org, Genf, [2000a, 15.4.2004](#)
- UNAIDS HIV DRUG ACCESS INITIATIVE: Providing Wider Access to HIV-related Drugs in Developing Countries. Pilot Phase. Report of the Meeting on the evaluation of the initiative, www.unaids.org, Genf, [2000b, 15.4.2004](#)

- UNAIDS: AIDS epidemic update 2003, UNAIDS/03.39E, www.unaids.org, Genf, [2003a](#), [12.2.2004](#)
- UNAIDS: Fact sheet: Children Orphaned by AIDS in sub-Saharan Africa, www.unaids.org, Genf, [2003b](#), [6.5.2004](#)
- UNAIDS: AIDS Epidemic Update, December 2004, www.unaids.org, Genf, [2004a](#), [8.2.2005](#)
- UNAIDS: Stepping back from the edge: the pursuit of antiretroviral therapy in Botswana, South Africa and Uganda, UNAIDS/04.04E, www.UNAIDS.org, Genf, [2004b](#), [8.2.2005](#)
- UNAIDS: 2004 Report on the Global AIDS Epidemic, www.unaids.org, Genf, [2004c](#), [8.2.2005](#)
- UNAIDS: Progress on global access to HIV Antiretroviral Therapy, an Update on "3 by 5", www.UNAIDS.org, Genf, [2005](#), [17.10.2005](#)
- UNDP: Human development report, <http://hdr.undp.org>, [2002](#), [6.5.2004](#)
- U.S. Census Bureau: The AIDS Pandemic in the 21st Century, www.census.gov, [2004](#), [17.10.2005](#)
- Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients, *AIDS*. [2003](#); *17 Suppl 3*:[55-61](#)
- Van der Geest S, Reynolds-Whyte S (Hrsg.): The Context of Medicines in Developing Countries. Studies in Pharmaceutical Anthropology, Dordrecht, Boston, London, Kluwer Academic Publishers, [1998](#): [S.392](#)
- Van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE: Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi, *Trop Med Int Health*. [2005](#); *10(5)*:[464-70](#)
- Van Rij RP, Visser JA, Naarding M, Schols D, Schuitemaker H: In vivo evolution of X4 HIV-1 variants in the natural course of infection coincides with reduced sensitivity to CXCR4 antagonists, Abstract 395, 9th CROI [2002](#), Seattle, USA

- Vergne L, Kane CT, Laurent C, Diakhate N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liegeois F, Ndir A, Laniece I, Peeters M, Ndoye I, Mboup S, Delaporte E: Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy, *AIDS*. [2003;17 Suppl 3:31-8](#)
- Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, Delaporte E: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries, *J Acquir Immune Defic Syndr*. [2002;29\(2\):165-8](#)
- Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study, *J Infect Dis*. [2001;183\(8\):1290-4](#)
- Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality, *J Infect Dis*. [1999;179\(3\):717-20](#)
- Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group, *N Engl J Med*. [1995;333\(7\):401-7](#)
- Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance, *JAMA*. [1998;279\(24\):1977-83](#)
- Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA: Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV, *Drug Metab Dispos*. [2005;33\(4\):587-95](#)
- Walsh JC, Mandalia S, Gazzard BG: Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome, *AIDS*. [2002;16\(2\):269-77](#)
- Warwick Z: The influence of antiretroviral therapy on the uptake of HIV testing in Botswana, Abstract 5476, 15th International AIDS Conference [2004](#), Bangkok, Thailand

- Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respass R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E: Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda, *AIDS*. [2003;17 Suppl 3:39-48](#)
- Weidle PJ, Kityo CM, Mugenyi P, Downing R, Kebba A, Pieniazek D, Respass R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, Lackritz E: Resistance to antiretroviral therapy among patients in Uganda, *J Acquir Immune Defic Syndr*. [2001;26\(5\):495-500](#)
- Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugenyi P, Mermin J, Samb B, Lackritz E: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance, *Lancet*. [2002;360\(9326\):34-40](#).
- Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana, *J Acquir Immune Defic Syndr*. [2003;34\(3\):281-8](#)
- WHO: WHO International Consultative Meeting on HIV/AIDS Antiretroviral Therapy. Report of the Meeting, WHO, Genf, [2001](#)
- WHO: Scaling up antiretroviral therapy in resource-limited countries, Guidelines for a public health approach, WHO, Genf, [2002a, S. 19](#)
- WHO: International Action Plan on Scaling-Up Access to HIV Care. A Commitment to Universal Access and Action on HIV/AIDS Treatment , WHO, www.who.org, Genf, [2002b, 20.3.2004](#)
- WHO: Scaling up antiretroviral therapy in resource-limited countries, Guidelines for a public health approach, Draft, WHO, Genf, [2002c, 11.5.2004](#)
- WHO: The World Health Report: 2004: Changing History, www.who.org, Genf, [2004a, 4.11.2005](#)
- WHO: Country Indicators, www-nt.who.int, [2004b, 5.7.2004](#)
- WHO/UNAIDS: Progress on Global Access to HIV Antiretroviral Therapy - an update on “3 by 5”, www.who.org, Genf, [2005a, 27.10.2005](#)

WHO/UNAIDS: The 3 by 5 Initiative – treat three million people living with HIV/AIDS by 2005, press release, www.who.org, Genf, 2005b, 4.11.2005

Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM: Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons, *J Infect Dis.* 1999:*179*(4):790-8

Wood E, Braitstein P, Montaner JS, Schechter MT, Tyndall MW, O'Shaughnessy MV, Hogg RS: Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa, *Lancet* 2000b:*355*(9221):2095-100

Wood E, Low-Beer S, Bartholomew K, Landolt M, Oram D, O'Shaughnessy MV, Hogg RS: Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver's West End, *Can J Public Health.* 2000a:*91*(2):125-8

Wood R, Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F: When to start highly active antiretroviral therapy in sub-Saharan Africa? Abstract 4617, 15th International AIDS Conference 2004, Bangkok, Thailand

Worldbank: Uganda at a glance, www.worldbank.org , 20.8.2003

Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel, *JAMA.* 2002:*288*(2):222-35

Yoshinaga T, Sato A, Fujishita T, Fujiwara T: S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development, Abstract 8, 9th CROI 2002, Seattle, USA

Zuniga JM: Assessing African clinician knowledge in ART delivery: results of the first round of GALEN Certification, Abstract 2443, 15th International AIDS Conference 2004, Bangkok, Thailand